Pictet Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-3,106
Closed -$41.5K – 2024
2024
Q2
$41.5K Hold
3,106
– – ﹤0.01% 1955
2024
Q1
$144K Hold
3,106
– – ﹤0.01% 1824
2023
Q4
$210K Hold
3,106
– – ﹤0.01% 1724
2023
Q3
$225K Buy
+3,106
New +$248K ﹤0.01% 1635

Other funds holding DNA

Pictet Asset Management's DNA Position: Q3 2024 in Review

Pictet Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 3,106 shares — an estimated $41.5K sold.

Pictet Asset Management first reported a position in DNA in Q3 2023 and held it in 4 quarters. The position peaked at $225K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Pictet Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Pictet Asset Management sold 3,106 Ginkgo Bioworks shares in Q3 2024, an estimated $41.5K.
  • Pictet Asset Management first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 4 quarters.
  • Pictet Asset Management's Ginkgo Bioworks position peaked at $225K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Pictet Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.